Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DTIL NASDAQ:MDWD NASDAQ:TCRT NASDAQ:VYGR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDTILPrecision BioSciences$7.29-0.5%$7.35$3.53▼$9.62$188.10M1.25663,807 shs192,288 shsMDWDMediWound$14.23-0.3%$14.71$13.54▼$20.96$182.88M0.1485,640 shs45,523 shsTCRTAlaunos Therapeutics$1.94+1.0%$2.25$1.67▼$4.59$47.38M-1.0215,787 shs14,056 shsVYGRVoyager Therapeutics$3.10+0.3%$3.53$2.88▼$5.55$187.31M1.27820,717 shs484,464 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDTILPrecision BioSciences0.00%-7.37%+8.00%+3.55%+47.57%MDWDMediWound0.00%-2.60%-2.47%-14.89%-32.24%TCRTAlaunos Therapeutics0.00%-5.37%-6.28%-29.71%-37.42%VYGRVoyager Therapeutics0.00%-2.21%-12.68%-18.21%-5.49%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDTILPrecision BioSciences$7.29-0.5%$7.35$3.53▼$9.62$188.10M1.25663,807 shs192,288 shsMDWDMediWound$14.23-0.3%$14.71$13.54▼$20.96$182.88M0.1485,640 shs45,523 shsTCRTAlaunos Therapeutics$1.94+1.0%$2.25$1.67▼$4.59$47.38M-1.0215,787 shs14,056 shsVYGRVoyager Therapeutics$3.10+0.3%$3.53$2.88▼$5.55$187.31M1.27820,717 shs484,464 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDTILPrecision BioSciences0.00%-7.37%+8.00%+3.55%+47.57%MDWDMediWound0.00%-2.60%-2.47%-14.89%-32.24%TCRTAlaunos Therapeutics0.00%-5.37%-6.28%-29.71%-37.42%VYGRVoyager Therapeutics0.00%-2.21%-12.68%-18.21%-5.49%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDTILPrecision BioSciences 2.60Moderate Buy$32.25342.39% UpsideMDWDMediWound 2.25Hold$34.00138.93% UpsideTCRTAlaunos Therapeutics 1.00SellN/AN/AVYGRVoyager Therapeutics 2.75Moderate Buy$16.50432.26% UpsideCurrent Analyst Ratings BreakdownLatest TCRT, DTIL, VYGR, and MDWD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/20/2026VYGRVoyager Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy7/17/2026MDWDMediWound Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/13/2026VYGRVoyager Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/9/2026DTILPrecision BioSciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/9/2026DTILPrecision BioSciences OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$20.005/29/2026TCRTAlaunos Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/28/2026MDWDMediWound HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$36.005/27/2026MDWDMediWound OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$33.00 ➝ $32.005/27/2026DTILPrecision BioSciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$60.005/26/2026VYGRVoyager Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/15/2026TCRTAlaunos Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)(Data available from 7/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDTILPrecision BioSciences$34.26M5.49N/AN/A$4.03 per share1.81MDWDMediWound$16.96M10.78N/AN/A$3.40 per share4.19TCRTAlaunos TherapeuticsN/AN/AN/AN/A$0.93 per shareN/AVYGRVoyager Therapeutics$40.37M4.64N/AN/A$3.53 per share0.88Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDTILPrecision BioSciences-$45.72M-$3.67N/AN/AN/A-96.73%-85.37%-37.34%8/6/2026 (Estimated)MDWDMediWound-$23.88M-$2.26N/AN/AN/A-180.30%-67.22%-31.87%8/13/2026 (Estimated)TCRTAlaunos Therapeutics-$4.18M-$2.13N/AN/AN/AN/A-165.94%-123.50%8/18/2026 (Estimated)VYGRVoyager Therapeutics-$119.72M-$1.97N/AN/AN/A-319.61%-55.97%-43.12%8/5/2026 (Estimated)Latest TCRT, DTIL, VYGR, and MDWD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2026Q2 2026MDWDMediWound-$0.76N/AN/AN/A$2.59 millionN/A8/6/2026Q2 2026DTILPrecision BioSciences-$0.71N/AN/AN/A$1.40 millionN/A8/5/2026Q2 2026VYGRVoyager Therapeutics-$0.55N/AN/AN/A$4.52 millionN/A5/27/2026Q1 2026MDWDMediWound-$0.65-$0.23+$0.42-$0.23$3.37 million$1.48 million5/15/2026Q1 2026TCRTAlaunos TherapeuticsN/A-$0.59N/A-$0.59N/AN/A5/7/2026Q1 2026VYGRVoyager Therapeutics-$0.54-$0.47+$0.07-$0.47$8.79 million$1.19 million5/5/2026Q1 2026DTILPrecision BioSciences-$0.6550-$0.75-$0.0950-$0.75$4.05 million$10.84 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthDTILPrecision BioSciencesN/AN/AN/AN/AN/AMDWDMediWoundN/AN/AN/AN/AN/ATCRTAlaunos TherapeuticsN/AN/AN/AN/AN/AVYGRVoyager TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDTILPrecision BioSciences0.2914.0214.02MDWDMediWoundN/A2.412.19TCRTAlaunos TherapeuticsN/A1.631.63VYGRVoyager TherapeuticsN/A8.428.42Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDTILPrecision BioSciences37.99%MDWDMediWound46.83%TCRTAlaunos Therapeutics27.72%VYGRVoyager Therapeutics48.03%Insider OwnershipCompanyInsider OwnershipDTILPrecision BioSciences2.70%MDWDMediWound9.20%TCRTAlaunos Therapeutics16.14%VYGRVoyager Therapeutics12.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDTILPrecision BioSciences20025.80 million25.11 millionNo DataMDWDMediWound8012.85 million11.67 millionOptionableTCRTAlaunos Therapeutics4024.42 million20.48 millionNo DataVYGRVoyager Therapeutics10060.42 million52.75 millionOptionableTCRT, DTIL, VYGR, and MDWD HeadlinesRecent News About These CompaniesVoyager Therapeutics (NASDAQ:VYGR) Stock Crosses Below 50 Day Moving Average - Here's What HappenedJuly 23 at 3:59 AM | marketbeat.comVoyager Therapeutics (NASDAQ:VYGR) Share Price Crosses Below 50-Day Moving Average - Should You Sell?July 15, 2026 | marketbeat.comVoyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer’s Disease Expected H2 2026July 13, 2026 | markets.businessinsider.comVoyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer's Disease Expected H2 2026July 13, 2026 | globenewswire.comCramer to a 23-Year-Old: Buy It, but It Might Take a ‘Lifetime’ to Make MoneyJuly 2, 2026 | aol.comACramer to a 23-Year-Old: Buy It, but It Might Take a ‘Lifetime' to Make MoneyJuly 2, 2026 | 247wallst.comVoyager Therapeutics (VYGR) is Amongst the Best Stocks Under $10, With More Than 50% UpsideJune 30, 2026 | finance.yahoo.comVoyager’s Tau-Targeted Gene Therapy VY1706 for Alzheimer’s Disease to Be Featured in Developing Topics Poster Presentation at AAIC 2026June 29, 2026 | markets.businessinsider.comVoyager's Tau-Targeted Gene Therapy VY1706 for Alzheimer's Disease to Be Featured in Developing Topics Poster Presentation at AAIC 2026June 29, 2026 | globenewswire.comVoyager to Present at H.C. Wainwright 7th Annual Neuro Perspectives Hybrid ConferenceJune 11, 2026 | globenewswire.comVoyager Therapeutics Highlights 2026 CNS Pipeline and StrategyJune 10, 2026 | theglobeandmail.comVoyager Therapeutics Expands Authorized Shares After Stockholder VoteJune 10, 2026 | tipranks.comHere's Why We're A Bit Worried About Voyager Therapeutics' (NASDAQ:VYGR) Cash Burn SituationJune 9, 2026 | finance.yahoo.comVoyager Receives FDA IND Clearance for VY1706, First Gene Therapy Approach to Reducing Tau Production in the Brain for Alzheimer’s DiseaseJune 1, 2026 | markets.businessinsider.comVoyager Therapeutics IND Cleared for Alzheimer’s Gene TherapyJune 1, 2026 | tipranks.comVoyager Receives FDA IND Clearance for VY1706, First Gene Therapy Approach to Reducing Tau Production in the Brain for Alzheimer's DiseaseJune 1, 2026 | globenewswire.comWhat Voyager Therapeutics Inc (VYGR) Has Gained on Its Therapy ProgramsMay 20, 2026 | finance.yahoo.comVoyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinical Trial in Alzheimer’s Disease Expected H2 2026May 13, 2026 | markets.businessinsider.comVoyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinical Trial in Alzheimer's Disease Expected H2 2026May 13, 2026 | globenewswire.comVoyager Therapeutics (VYGR) Reports Q1 Loss, Misses Revenue EstimatesMay 7, 2026 | zacks.comVoyager Reports First Quarter 2026 Financial and Operating ResultsMay 7, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTCRT, DTIL, VYGR, and MDWD Company DescriptionsPrecision BioSciences NASDAQ:DTIL$7.29 -0.04 (-0.55%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$7.26 -0.03 (-0.34%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.MediWound NASDAQ:MDWD$14.23 -0.04 (-0.28%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$14.22 -0.02 (-0.11%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.Alaunos Therapeutics NASDAQ:TCRT$1.94 +0.02 (+1.04%) Closing price 07/24/2026 03:59 PM EasternExtended Trading$1.88 -0.05 (-2.84%) As of 07/24/2026 05:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology. The company was founded in 2003 and is headquartered in Houston, Texas.Voyager Therapeutics NASDAQ:VYGR$3.10 +0.01 (+0.32%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$3.10 +0.00 (+0.16%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/20- 07/24 Telecom Earnings Reveal a Sector That Finally Looks Healthier AMD and Cerbras Create A New Blueprint For Hardware Intel Earnings Reveal Whether the Chip Selloff Created a Buy CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test Defense Earnings Show Readiness Now and Modernization Ahead Freeport McMoRan Post-Earnings: Why Good Enough May Finally Be Good Enough Tesla Just Delivered Record Sales—So Why Did the Stock Sell Off? Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
